TORONTO -- A substantial proportion of multiple myeloma patients undergoing treatment with bispecific antibodies had sustained remissions when they discontinued therapy before disease progression, ...
Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at near ...
Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results